DrugPatentWatch Database Preview

ZYKADIA Drug Profile

« Back to Dashboard

When do Zykadia patents expire, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are twelve patents protecting this drug.

This drug has three hundred and ninety-one patent family members in fifty-five countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

Summary for ZYKADIA

International Patents:	391
US Patents:	12
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	67
Clinical Trials:	9
Patent Applications:	68
Drug Prices:	Drug price information for ZYKADIA
Prior Art and Litigation Support	Order Prior Art and Litigation support for ZYKADIA
DailyMed Link:	ZYKADIA at DailyMed

Generic Entry Opportunity Date for ZYKADIA

NDA:

205755

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZYKADIA

Drug Class	Kinase Inhibitor
Mechanism of Action	Tyrosine Kinase Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 2C9 Inhibitors

Synonyms for ZYKADIA

1032900-25-6

1431456-10-8

2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-

2510AH

4CA-0729

4MK

5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine

5-chloro-N(2)-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N(4)-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

5-Chloro-N~2~-[5-Methyl-4-(Piperidin-4-Yl)-2-(Propan-2-Yloxy)phenyl]-N~4~-[2-(Propan-2-Ylsulfonyl)phenyl]pyrimidine-2,4-Diamine

5-Chloro-N~2~-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N~4~-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine

5-Chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine

5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine

5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine

AB0096053

AC-27469

AK174337

AKOS025396438

AOB31713

BC600329

BCP07611

BDBM50436850

C28H36ClN5O3S

ceritinib

Ceritinib (JAN/USAN/INN)

Ceritinib [USAN:INN]

Ceritinib(LDK378)

ceritinibum

CHEBI:78432

CHEMBL2403108

compound 15b [PMID 23742252]

CS-1406

D10551

DB09063

DTXSID10725373

Eritinib (LDK378)

EX-A187

FT-0697208

GS-6356

GTPL7397

HMS3652H22

HY-15656

J-690011

K418KG2GET

KB-13070

LDK 378

LDK-378

LDK-378|||Zykadia

LDK378

LDK378 Certinib

LDK378(Ceritinib)

MolPort-035-395-774

N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide

N-{2-Methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenyl-2-quinazolinyl)amino]benzamide

NCGC00351603-10

NCGC00351603-15

NVP-LDK378-NX

QC-5183

S7083

SB16490

SC-93949

SCHEMBL1014329

SW219725-1

SYN1199

UNII-K418KG2GET

VERWOWGGCGHDQE-UHFFFAOYSA-N

W-6123

ZINC96272772

Zykadia (TN)

US Patents and Regulatory Information for ZYKADIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes			Y	Y
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes			Y	Y
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes			Y	Y
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes			Y	Y
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes

International Patents for ZYKADIA

Country	Patent Number	Estimated Expiration
Denmark	2281563
Iceland	2923
Russian Federation	2400477
Croatia	P20120335
European Patent Office	3453708
Brazil	PI0722384
Portugal	2281563

Supplementary Protection Certificates for ZYKADIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2091918	92785	Luxembourg		PRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
2091918	300763	Netherlands		PRODUCT NAME: CERITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/999 20150508
1272477	529	Finland
2091918	CA 2015 00047	Denmark		PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506
2091918	PA2015034	Lithuania		PRODUCT NAME: CERITINIBUM; REGISTRATION NO/DATE: EU/1/15/999 20150506
1272477	15C0064	France		PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/999 20150508
2091918	2015/047	Ireland		PRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION: IRELAND EU/1/15/999 (C(2015) 3218), 20150506